Literature DB >> 25649244

Adherence to prophylaxis and quality of life in children and adolescents with severe haemophilia A.

M García-Dasí1, J A Aznar1, V Jiménez-Yuste2, C Altisent3, S Bonanad1, E Mingot4, F Lucía5, F Giménez6, M Fernanda López7, P Marco8, R Pérez9, M Á Fernández10, M J Paloma11, B Galmes12, S Herrero13, J A García-Talavera14.   

Abstract

Treatment adherence in adolescents with chronic diseases is around 50%, and failure is more common in preventive therapy. In haemophilia, contradictory results are reported by the published studies. The objective of this study was to evaluate adherence with factor VIII (FVIII) prophylaxis in Spanish patients with severe haemophilia A between age 6 and 20 years. Data were collected retrosp-ectively in the previous 2 years. The primary endpoint was the absolute adherence index (AAI), and the endpoints were related to clinical status, age, prophylaxis regimen, responsibility for factor administration and quality of life (QoL), assessed by the Haemo-QoL questionnaires. A total of 78 patients from 14 Spanish hospitals were recruited. Adherence ranged between -64.4 and 66.7 (mean -3.08). No differences were observed between children and adolescents (7.11 vs. 6.39; P = 0.809). A statistically significant association (P < 0.010) between infra adherent group and target joint was found, as was a statistically significant difference (P < 0.010) between the number of bleeding episodes experienced by the adherent group (mean 1.4) and by infra adherents (mean 4.5). There was no significant difference between AAI and prophylactic regimen (6.35 vs. 6.96, P = 0.848), neither between AAI and the person responsible for factor administration (5.57 vs. 8.79, P = 0.326). The Haemo-QoL scores (8-12 years) were related to adherence level (P < 0.05). Adherence was approximately ideal and patients perceived a high QoL. Because of the repercussions for compliance, it is essential to work during puberty on emotional and self-acceptance aspects of the disease, as well as coping, and the patient's family, school and health team relationships.
© 2015 John Wiley & Sons Ltd.

Entities:  

Keywords:  adherence; adolescents; children; haemophilia; prophylaxis; quality of life

Mesh:

Substances:

Year:  2015        PMID: 25649244     DOI: 10.1111/hae.12618

Source DB:  PubMed          Journal:  Haemophilia        ISSN: 1351-8216            Impact factor:   4.287


  13 in total

1.  Physical activity improved by adherence to prophylaxis in an Italian population of children, adolescents and adults with severe haemophilia A: the SHAPE Study.

Authors:  Ezio Zanon; Annarita Tagliaferri; Samantha Pasca; Cosimo P Ettorre; Lucia D Notarangelo; Chiara Biasioli; Anna B Aru; Marta Milan; Silvia Linari; Angiola Rocino; Fabio Gagliano; Giovanni Di Minno; Gabriella Gamba; Rita C Santoro; Piercarla Schinco; Marco Marietta; Axel Seuser; Sylvia von Mackensen
Journal:  Blood Transfus       Date:  2019-06-05       Impact factor: 3.443

2.  Design and Usability of an Electronic Health Record-Integrated, Point-of-Care, Clinical Decision Support Tool for Modeling and Simulation of Antihemophilic Factors.

Authors:  Susan M Abdel-Rahman; Harpreet Gill; Shannon L Carpenter; Pathe Gueye; Brian Wicklund; Matt Breitkreutz; Arindam Ghosh; Avinash Kollu
Journal:  Appl Clin Inform       Date:  2020-04-08       Impact factor: 2.342

3.  Factor VIII prophylaxis effects outweigh other hemostasis contributors in predicting severe haemophilia A joint outcomes.

Authors:  Beth Boulden Warren; Linda Jacobson; Christine Kempton; George R Buchanan; Michael Recht; Deborah Brown; Cindy Leissinger; Amy D Shapiro; Thomas C Abshire; Marilyn J Manco-Johnson
Journal:  Haemophilia       Date:  2019-05-21       Impact factor: 4.263

4.  Motivational techniques to improve self-care in hemophilia: the need to support autonomy in children.

Authors:  Sarah Bérubé; Florine Mouillard; Claudine Amesse; Serge Sultan
Journal:  BMC Pediatr       Date:  2016-01-11       Impact factor: 2.125

Review 5.  Treatment adherence in hemophilia.

Authors:  Courtney D Thornburg; Natalie A Duncan
Journal:  Patient Prefer Adherence       Date:  2017-09-27       Impact factor: 2.711

6.  BAY 81-8973 prophylaxis and pharmacokinetics in haemophilia A: Interim results from the TAURUS study.

Authors:  Cristina Santoro; Beng Fuh; Phu Quoc Le; Philip Maes; Rubén Berrueco; Eva Maria Mingot-Castellano; Sylvia von Mackensen; Alexander Solms; Michael Wang
Journal:  Eur J Haematol       Date:  2020-04-23       Impact factor: 2.997

Review 7.  Personalised Prophylaxis in a Child with Haemophilia A and Type 1 Diabetes.

Authors:  Maria Sol Cruz; Josefina Santillan; Julieta Lesser; Juan Pablo Ortiz; Laura Forzani
Journal:  Clin Pract       Date:  2021-05-08

Review 8.  Factor VIII replacement prophylaxis in patients with hemophilia A transitioning to adults: a systematic literature review.

Authors:  Jing Sun; Xuan Zhou; Nan Hu
Journal:  Orphanet J Rare Dis       Date:  2021-06-26       Impact factor: 4.123

Review 9.  Categorizing factors of adherence to parenteral treatment in growth hormone deficiencies and hemophilia: What should be the targets for future research?

Authors:  Serge Sultan; Mira El-Hourani; Émélie Rondeau; Nicolas Garnier
Journal:  Patient Prefer Adherence       Date:  2018-10-08       Impact factor: 2.711

10.  Hemophilia prophylaxis adherence and bleeding using a tailored, frequency-escalated approach: The Canadian Hemophilia Primary Prophylaxis Study.

Authors:  Saunya Dover; Victor S Blanchette; Darius Wrathall; Eleanor Pullenayegum; Daniel Kazandjian; Byron Song; Sue Ann Hawes; Stéphanie Cloutier; Geroges E Rivard; Robert J Klaassen; Elizabeth Paradis; Nicole Laferriere; Ann Marie Stain; Anthony K Chan; Sara J Israels; Roona Sinha; MacGregor Steele; John K M Wu; Brian M Feldman
Journal:  Res Pract Thromb Haemost       Date:  2020-01-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.